Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Florence R WilsonMegan E CoombesChristine Brezden-MasleyMariya YurchenkoQuinlan WylieReuben DoumaAbhishek VaruBrian HuttonBecky SkidmoreChris CameronPublished in: Systematic reviews (2018)
PROSPERO CRD42017055763.